The clinical utility of apoB versus LDL-C/non-HDL-C
Abstract
The ESC/EAS Guidelines and the EAS/EFLM consensus reports state that apoB is a more accurate marker of cardiovascular risk than LDL-C or non-HDL-C and that apoB can be measured accurately and precisely than LDL-C or non-HDL-C. Nevertheless, EAS/EFLM called for a randomized clinical trial and a cost-effective analysis before widespread implementation of apoB. To analyse these issues from the perspective of clinical utility as clinical utility...
Paper Details
Title
The clinical utility of apoB versus LDL-C/non-HDL-C
Published Date
Sep 1, 2020
Journal
Volume
508
Pages
103 - 108
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History